HEPA — Hepion Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $3.11m
- $7.30m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -1301.53% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on artificial intelligence (AI)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic diseases. Its primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models. Its drug candidate is intended to target multiple molecular pathways across the full spectrum of liver disease progression, from the triggering events that initiate disease to the pathological events that directly impair liver function and integrity. Its AI-POWR platform provides integrative, multi-variate, systems-biology bioinformatic and big-data analysis of proprietary pre-clinical and clinical data with publicly available multi-omic databases.
Directors
- Gary Jacob NEC (74)
- Robert Foster CEO (62)
- John Cavan CFO (62)
- Todd Hobbs OTH
- Timothy Block IND (66)
- John Brancaccio IND (73)
- Arnold Lippa IND (74)
- Petrus Wijngaard IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 15th, 2013
- Public Since
- February 7th, 2014
- No. of Shareholders
- 659
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,927,276
- Address
- 399 Thornall St, EDISON, 08837-2236
- Web
- https://hepionpharma.com/
- Phone
- +1 7329024000
- Auditors
- Grassi & Co., CPAs, P.C.
Upcoming Events for HEPA
Hepion Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Hepion Pharmaceuticals Inc Earnings Release
Similar to HEPA
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Hepion Pharmaceuticals share price?
As of Today at 21:05 UTC, shares in Hepion Pharmaceuticals are trading at $0.28. This share price information is delayed by 15 minutes.
How has the Hepion Pharmaceuticals share price performed this year?
Shares in Hepion Pharmaceuticals last closed at $0.28 and the price had moved by -99.63% over the past 365 days. In terms of relative price strength the Hepion Pharmaceuticals share price has underperformed the S&P500 Index by -99.66% over the past year.
What are the analyst and broker recommendations for Hepion Pharmaceuticals?
The overall consensus recommendation for Hepion Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Hepion Pharmaceuticals dividend yield?
Hepion Pharmaceuticals does not currently pay a dividend.
Does Hepion Pharmaceuticals pay a dividend?
Hepion Pharmaceuticals does not currently pay a dividend.
When does Hepion Pharmaceuticals next pay dividends?
Hepion Pharmaceuticals does not currently pay a dividend.
How do I buy Hepion Pharmaceuticals shares?
To buy shares in Hepion Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Hepion Pharmaceuticals?
As of the previous close price of $0.28, shares in Hepion Pharmaceuticals had a market capitalisation of $3.11m.
Where are Hepion Pharmaceuticals shares listed?
Here are the trading details for Hepion Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HEPA
What kind of share is Hepion Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Hepion Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Hepion Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Hepion Pharmaceuticals is $30.00. That is 10441.11% above the last closing price of $0.28.
Analysts covering Hepion Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$5.20 for the next financial year.
Find out moreWhat is the trend in the Hepion Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hepion Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -99.12%.
As of the last closing price of $0.28, shares in Hepion Pharmaceuticals were trading -98.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Hepion Pharmaceuticals PE Ratio?
The Hepion Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.28.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Hepion Pharmaceuticals?
Hepion Pharmaceuticals' management team is headed by:
- Gary Jacob - NEC
- Robert Foster - CEO
- John Cavan - CFO
- Todd Hobbs - OTH
- Timothy Block - IND
- John Brancaccio - IND
- Arnold Lippa - IND
- Petrus Wijngaard - IND